Bosutinib

Bosutinib
Clinical data
Trade names	Bosulif
License data	US FDA: Bosutinib;
Routes of; administration	Oral
ATC code	L01XE14 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;
CAS Number	380843-75-4 ;
PubChem CID	5328940;
ChemSpider	4486102 ;
UNII	5018V4AEZ0;
ChEBI	CHEBI:39112 ;
ChEMBL	ChEMBL288441 ;
CompTox Dashboard (EPA)	DTXSID10861568 ;
ECHA InfoCard	100.149.122
Chemical and physical data
Formula	C26H29Cl2N5O3
Molar mass	530.446 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1c(OC)cc(c(Cl)c1)Nc4c(C#N)cnc3cc(OCCCN2CCN(CC2)C)c(OC)cc34;
	InChI InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31) ; Key:UBPYILGKFZZVDX-UHFFFAOYSA-N ;
	(what is this?) (verify)

Bosutinib (rINN/USAN; codenamed SKI-606, marketed under the trade name Bosulif) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.^[1]

It is being developed by Pfizer. Some commercial stocks of bosutinib (from sources other than the Pfizer material) have recently been found to have the incorrect chemical structure, calling the biological results obtained with them into doubt.^[2]

Bosutinib received FDA approval on September for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.^[3]

References

^ Vultur A, Buettner R, Kowolik C; et al. (2008). "SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells". Mol. Cancer Ther. 7 (5): 1185–94. doi:10.1158/1535-7163.MCT-08-0126. PMC 2794837. PMID 18483306. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Derek Lowe, In The Pipeline (blog), "Bosutinib: Don't Believe the Label!"
^ "Bosulif Approved for Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia". 05 Sep 2012. {{cite news}}: Check date values in: |date= (help)

External links

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[pmid18483306-1] Vultur A, Buettner R, Kowolik C; et al. (2008). "SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells". Mol. Cancer Ther. 7 (5): 1185–94. doi:10.1158/1535-7163.MCT-08-0126. PMC 2794837. PMID 18483306. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[2] Derek Lowe, In The Pipeline (blog), "Bosutinib: Don't Believe the Label!"

[3] "Bosulif Approved for Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia". 05 Sep 2012. {{cite news}}: Check date values in: |date= (help)

[1]

[2]

[3]

See also

References

External links